Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

M. Dinis-Ribeiro; M. Areia; A. C. de Vries; R. Marcos-Pinto; M. Monteiro-Soares; A. O’Connor; C. Pereira; P. Pimentel-Nunes; R. Correia; A. Ensari; J. M. Dumonceau; J. C. Machado; G. Macedo; P. Malfertheiner; T. Matysiak-Budnik; F. Megraud; K. Miki; C. O’Morain; R. M. Peek; T. Ponchon; A. Ristimaki; B. Rembacken; F. Carneiro; E. J. Kuipers

doi:10.1055/s-0031-1291491

Endoscopy, Table of Contents

Endoscopy 2012; 44(01): 74-94
DOI: 10.1055/s-0031-1291491

Guideline

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

M. Dinis-Ribeiro^*

¹Department of Gastroenterology, Portuguese Oncology Institute of Porto, Portugal

⁵Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal

,

M. Areia

²Department of Gastroenterology, Portuguese Oncology Institute of Coimbra, Portugal

⁵Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal

,

A. C. de Vries

³Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands

,

R. Marcos-Pinto

⁴Department of Gastroenterology, Centro Hospitalar do Porto, Portugal

⁶Institute of Biomedical Sciences, University of Porto (ICBAS/UP), Porto, Portugal

,

M. Monteiro-Soares

⁵Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal

,

A. O’Connor

⁷AMNCH/TCD, Adelaide and Meath Hospital/Trinity College, Gastroenterology Department, Dublin, Ireland

,

C. Pereira

⁸Molecular Oncology Research Group, Portuguese Oncology Institute of Porto, Portugal

,

P. Pimentel-Nunes

¹Department of Gastroenterology, Portuguese Oncology Institute of Porto, Portugal

,

R. Correia

⁵Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal

,

A. Ensari^†

⁹Department of Pathology, Ankara University Medical School, Ankara, Turkey

,

J. M. Dumonceau^‡

¹⁰Département de Gastroénterologie et d’Hépatopancréatologie, H.U.G. Hôpital Cantonal, Geneve, Switzerland

,

J. C. Machado

¹¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

,

G. Macedo^§

¹²Department of Gastroenterology, Centro Hospitalar S. João/Medical Faculty, Porto, Portugal

,

P. Malfertheiner

¹³Klinik der Gasroenterologie, Hepatologie und Infektologie, Otto von Guericke Universität Magdeburg, Magdeburg, Germany

,

T. Matysiak-Budnik

¹⁴Service d’Hépato-Gastroentérologie, Hôtel Dieu, CHU de Nantes, Nantes, France

,

F. Megraud

¹⁵Inserm U853 & Université Bordeaux, Laboratoire de Bacteriologie, Bordeaux, France

,

K. Miki

¹⁶Japan Research Foundation of Prediction, Diagnosis and Therapy for Gastric Cancer (JRF PDT GC), Tokyo, Japan

,

C. O’Morain

⁷AMNCH/TCD, Adelaide and Meath Hospital/Trinity College, Gastroenterology Department, Dublin, Ireland

,

R. M. Peek

¹⁷Division of Gastroenterology, Vanderbilt University School of Medicine, Nashville, USA

,

T. Ponchon

¹⁸Hôpital Edouard Herriot, Department of Digestive Diseases, Lyon, France

,

A. Ristimaki

¹⁹Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

²⁰Genome-Scale Biology, Research Program Unit, University of Helsinki, Helsinki, Finland

,

B. Rembacken

²¹Centre for Digestive Diseases, The General Infirmary at Leeds, Leeds, United Kingdom

,

F. Carneiro^§

¹¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

²²Department of Pathology, Medical Faculty/Centro Hospitalar S. João, Porto, Portugal

,

E. J. Kuipers^**

³Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands

› Author Affiliations

Abstract

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter Study Group (EHSG), the European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach (termed MAPS). A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia, and the need for adequate staging in the case of high grade dysplasia, and they focus on treatment and surveillance indications and methods.

Full Text

References

References
1 Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560
2 Collaboration AGREE. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23
3 Atkins D, Best D, Briss PA et al. GRADE Working Group Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
4 Guyatt GH, Oxman AD, Vist GE et al. GRADE working group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926
5 Harbour R, Miller J. A new system for grading recommendations in evidence-based guidelines. BMJ 2001; 323: 334-336
6 Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740
7 Kapadia CR. Gastric atrophy, metaplasia and dysplasia. A clinical perspective. J Clin Gastroenterol 2003; 36: 29-36
8 Carneiro F, Machado JC, David L et al. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev 2001; 10: 101-102
9 Ihamäki T, Saukkonen M, Siurala M. Long term observation of subjects with normal mucosa and with superficial gastritis: results of 23–27 years follow-up examination. Scand J Gastroenterol 1978; 13: 771-775
10 Ormiston MC, Gear MW, Codling BW. Five year follow-up study of gastritis. J Clin Pathol 1982; 35: 757-760
11 Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49
12 Fukao A, Hisamichi S, Ohsato M et al. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 1993; 4: 17-20
13 Genta RM. Review article: gastric atrophy and atrophic gastritis—nebulous concepts in search of a definition. Aliment Pharmacol Ther 1998; 12: 17-23
14 Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1994; 20: 1161-1181
15 Misiewicz JJ. The Sydney System: a new classification of gastritis. Introduction. J Gastroenterol Hepatol 1991; 6: 207-208
16 Plummer M, Buiatti E, Lopez G et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol 1997; 26: 716-720
17 Filipe MI, Potet F, Bogomoletz WV et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 1985; 26: 1319-1326
18 Filipe MI, Barbatis C, Sandey A et al. Expression of intestinal mucin antigens in the gastric epithelium and its relationship with malignancy. Hum Pathol 1988; 19: 19-26
19 Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric alcer. A follow up study. Gut 1990; 31: 1097-1104
20 Reis CA, David L, Correa P et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC and MUC6) expression. Cancer Res 1999; 59: 1003-1007
21 Gutiérrez-González L, Wright NA. Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 2008; 40: 510-522
22 Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 1985; 12: 2-10
23 Genta RM, Rugge M. Gastric precancerous lesions: heading for an international consensus. Gut 1999; 45: 15-18
24 Guindi M, Riddell RH. The pathology of epithelial pre-malignancy of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2001; 15: 191-210
25 Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology and problems. Am J Gastroenterol 1996; 91: 864-872
26 Odze RD, Riddell RH, Bosman FT et al. (ed.) Premalignant lesions of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, (ed) WHO Classification of Tumours of the Digestive System. 4. edn. Lyon: IARC Press; 2010
27 Park SY, Jeon SW, Jung MK et al. Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. Eur J Gastroenterol Hepatol 2008; 20: 966-970
28 de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134: 945-952
29 Yamada H, Ikegami M, Shimoda T et al. Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy 2004; 36: 390-396
30 Dinis-Ribeiro M, Lopes C, da Costa-Pereira A et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 2004; 57: 177-182
31 Whiting JL, Sigurdsson A, Rowlands DC et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50: 378-381
32 You WC, Li JY, Blot WJ et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 1999; 83: 615-619
33 Kokkola A, Haapiainen R, Laxén F et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow-up study. J Clin Pathol 1996; 49: 979-984
34 Rugge M, Farinati F, Baffa R et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994; 107: 1288-1296
35 Bearzi I, Brancorsini D, Santinelli A et al. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract 1994; 190: 61-68
36 Di Gregorio C, Morandi P, Fante R et al. Gastric dysplasia. a follow-up study. Am J Gastroenterol 1993; 88: 1715-1719
37 Fertitta AM, Comin U, Terruzzi V et al. Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy 1993; 25: 265-268
38 Farinati F, Rugge M, Di Mario F et al. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D. – Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy 1993; 25: 261-264
39 Rugge M, Farinati F, Di Mario F et al. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991; 22: 1002-1008
40 Rugge M, Baffa R, Farinati F et al. Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. Ital J Gastroenterol 1991; 23: 70-73
41 Koch HK, Oehlert M, Oehlert W. An evaluation of gastric dysplasia in the years 1986 and 1987. Pathol Res Pract 1990; 186: 80-84
42 Lansdown M, Quirke P, Dixon MF et al. High grade dysplasia of the gastric mucosa: a marker for gastric adenocarcinoma. Gut 1990; 31: 977-983
43 Coma del Corral MJ, Pardo-Mindan FJ, Razquin S et al. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 1990; 65: 2078-2085
44 Correa P, Haenszel W, Cuello C et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50: 4737-4740
45 Saraga EP, Gardiol D, Costa J. Gastric dysplasia. A histological follow-up study. Am J Surg Pathol 1987; 11: 788-796
46 Andersson AP, Lauritsen KB, West F et al. Dysplasia in gastric mucosa: prognostic significance. Acta Chir Scand 1987; 153: 29-31
47 Aste H, Sciallero S, Pugliese V et al. The clinical significance of gastric epithelial dysplasia. Endoscopy 1986; 18: 174-176
48 Farini R, Pagnini CA, Farinati F et al. Is mild gastric epithelial dysplasia an indication for follow-up?. J Clin Gastroenterol 1983; 5: 307-310
49 Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968
50 Lauwers GY, Shimizu M, Correa P et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 1999; 23: 511-518
51 Lauwers GY, Carneiro F, Graham DY et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, (eds.) WHO Classification of tumours of the digestive system. 4. edn. Lyon: IARC Press; 2010: 48-58
52 Atkins L, Benedict EB. Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med 1956; 254: 641-644
53 Bah A, Saraga E, Armstrong D et al. Endoscopic features of Helicobacter pylori-related gastritis. Endoscopy 1995; 27: 593-596
54 Calabrese C, Di Febo G, Brandi G et al. Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Ital J Gastroenterol Hepatol 1999; 31: 359-365
55 Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108: 917-924
56 Loffeld RJ. Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Neth J Med 1999; 54: 96-100
57 Redéen S, Petersson F, Jönsson KA et al. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003; 35: 946-950
58 Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc 1990; 36: 544-545
59 Eshmuratov A, Nah JC, Kim N et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci 2010; 55: 1364-1375
60 Yan SL, Wu ST, Chen CH et al. Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopy. World J Gastroenterol 2010; 16: 496-500
61 Laine L, Cohen H, Sloane R et al. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc 1995; 42: 420-423
62 Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003; 57: 498-504
63 Areia M, Amaro P, Dinis-Ribeiro M et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc 2008; 67: 1011-1018
64 Mouzyka S, Fedoseeva A. Chromoendoscopy with hematoxylin in the classification of gastric lesions. Gastric Cancer 2008; 11: 15-21 discussion 21–22
65 Tanaka K, Toyoda H, Kadowaki S et al. Surface pattern classification by enhanced magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc 2008; 67: 430-437
66 Anagnostopoulos GK, Yao K, Kaye P et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy 2007; 39: 202-207
67 Gonen C, Simsek I, Sarioglu S et al. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter 2009; 14: 12-21
68 Tahara T, Shibata T, Nakamura M et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 2009; 70: 246-253
69 Bansal A, Ulusarac O, Mathur S et al. Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. Gastrointest Endosc 2008; 67: 210-216
70 Kato M, Kaise M, Yonezawa J et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72: 523-529
71 Ezoe Y, Muto M, Horimatsu T et al. Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc 2010; 71: 477-484
72 Kadowaki S, Tanaka K, Toyoda H et al. Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol 2009; 24: 1625-1630
73 Uedo N, Ishihara R, Iishi H et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006; 38: 819-824
74 Okubo M, Tahara T, Shibata T et al. Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J Gastroenterol 2011; 46: 175-182
75 Kaise M, Kato M, Urashima M et al. Magnifying endoscopy combined with narrow-band imaging for differential diagnosis of superficial depressed gastric lesions. Endoscopy 2009; 41: 310-315
76 Capelle LG, Haringsma J, da Vries AC et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci 2010; 55: 3442-3448
77 Alaboudy AA, Elbahrawy A, Matsumoto S et al. Conventional narrow-band imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Dig Dis Sci 2011; 56: 1127-1130
78 Eriksson NK, Färkkilä MA, Voutilainen ME et al. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 2005; 37: 532-536
79 Guarner J, Herrera-Goepfert R, Mohar A et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 2003; 34: 28-31
80 el-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30: 72-77
81 Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228-233
82 Kashin S, Pavlov A, Gono K, Nadezhin A. Endoscopic diagnosis of early gastric cancer and gastric precancerous lesions. In: Pasechnikov VD, ed. Gastric cancer: diagnosis, early prevention, and treatment. 1. edn. New York: Nova Science Publishers; XXXHauppauge?XXX 2010: 197-233
83 Satoh K, Kimura K, Taniguchi Y et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998; 93: 569-573
84 de Vries AC, Haringsma J, de Vries RA et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010; 15: 259-264
85 Rugge M, Cassaro M, Pennelli G et al. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 2003; 52: 1387-1388
86 Ricuarte O, Gutierrez O, Cardona H et al. Atrophic gastritis in young children and adolescents. J Clin Pathol 2005; 58: 1189-1193
87 You WC, Blot WJ, Li JY et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993; 53: 1317-1321
88 Dursun M, Yilmaz S, Yükselen V et al. Evaluation of optimal gastric mucosal biopsy site and number for identification of Helicobacter pylori, gastric atrophy and intestinal metaplasia. Hepatogastroenterology 2004; 51: 1732-1735
89 el-Zimaity HM, al-Assi MT, Genta RM et al. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995; 90: 1962-1964
90 el-Zimaity HM, Ota H, Graham DY et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002; 94: 1428-1436
91 el-Zimaity HM, Ramchatesingh J, Saeed MA et al. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001; 54: 679-683
92 Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40: 650-658
93 Rugge M, Genta RM OLGA groupe Staging gastritis: an international proposal. Gastroenterology 2005; 129: 1807-1808
94 Rugge M, Meggio A, Pennelli G et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636
95 Satoh K, Osawa H, Yoshizawa M et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008; 13: 225-229
96 Rugge M, de Boni M, Pennelli G et al. Gastritis OLGA-staging and gastric cancer risk: a twelve year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104-1111
97 el-Zimaity HM, Graham DY, al-Assi MT et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27: 35-41
98 Capelle LG, de Vries AC, Haringsma J et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-1158
99 Guarner J, Herrera-Goepfert R, Mohar A et al. Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol 1999; 30: 1431-1434
100 Dinis-Ribeiro M, Yamaki G, Miki K et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11: 141-147
101 Graham DY, Nurgalieva ZZ, El-Zimaity HM et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006; 4: 306-314
102 Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174-179
103 Hartleb M, Wandzel P, Waluga M et al. Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies. Acta Gastroenterol Belg 2004; 67: 320-326
104 Iijima K, Abe Y, Kikuchi R et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 2009; 15: 853-859
105 Inoue M, Kobayashi S, Matsuura A et al. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev 1998; 7: 261-263
106 Kim HY, Kim N, Kang JN et al. Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol 2009; 21: 606-612
107 Knight T, Wyatt J, Wilson A et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 1996; 73: 819-824
108 Leja M, Kupcinkas L, Funka K et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009; 54: 2377-2384
109 Ley C, Mohar A, Guarner J et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev 2001; 10: 107-112
110 Nardone G, Rocco A, Staibano S et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 2005; 22: 1139-1146
111 Pasechnikov VD, Chukov SZ, Kotelevets SM et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 2005; 40: 297-301
112 Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99: 1910-1915
113 Rollan A, Ferreccio C, Gederlini A et al. Noninvasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol 2006; 12: 7172-7178
114 Sierra R, Une C, Ramírez V et al. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clin Exp Med 2006; 6: 72-78
115 Sitas F, Smallwood R, Jewell D et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev 1993; 2: 119-123
116 Storskrubb T, Aro P, Ronkainen J et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008; 43: 1448-1455
117 Sun LP, Gong YH, Wang L et al. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. World J Gastroenterol 2007; 13: 6562-6567
118 Wu KC, Li HT, Qiao TD et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis 2004; 5: 22-27
119 Väänänen H, Vauhkonen M, Helske T et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-891
120 Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007; 8: 15-22
121 Chung HW, Kim JW, Lee JH et al. Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J Clin Gastroenterol 2009; 43: 19-26
122 Kiyohira K, Yoshihara M, Ito M et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis: evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 2003; 38: 332-338
123 Oksanen A, Sipponen P, Miettinen A et al. Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol 2000; 35: 791-795
124 Di Mario F, Cavallar LG, Moussa AM et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 2006; 51: 1791-1795
125 Kreuning J, Lindeman J, Biemond I et al. Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci 1995; 40: 609-614
126 Con SA, Con-Wong R, Con-Chin GR et al. Serum pepsinogen levels, Helicobacter pylori CagA status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev 2007; 16: 2631-2636
127 Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004; 6: 449-456
128 Urita Y, Hike K, Torii N et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004; 49: 795-801
129 de Vries AC, Haringsma J, de Vries RA et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 2009; 70: 18-25
130 Watabe H, Mitsushima T, Yamaji Y et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-768
131 Yamaji Y, Watabe H, Yoshida H et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter 2009; 14: 81-86
132 Yanaoka K, Oka M, Mukoubayashi C et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17: 838-845
133 Yanaoka K, Oka M, Yoshimura N et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008; 123: 917-926
134 Ohata H, Kitauchi S, Yoshimura N et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 138-143
135 Oishi Y, Kiyohara Y, Kubo M et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163: 629-637
136 Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2007; 22: 1594-1604
137 Miki K, Fujishiro M, Kodashima S et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009; 21: 78-81
138 Aromaa A, Kosunen TU, Knekt P et al. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996; 144: 142-149
139 Fukuda H, Saito D, Hayashi S et al. Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case–control study in Japan. Jpn J Cancer Res 1995; 86: 64-71
140 Kikuchi S, Wada O, Miki K et al. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 1994; 73: 2695-2702
141 Knekt P, Teppo L, Aromaa A et al. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 2006; 119: 702-705
142 Kodoi A, Yoshihara M, Sumii K et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995; 30: 452-460
143 Kokkola A, Louhimo J, Puolakkainen P et al. Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol 2005; 11: 1032-1036
144 Kwak MS, Kim N, Lee HS et al. Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. Dig Dis Sci 2010; 55: 2275-2282
145 Miki K, Ichinose M, Kawamura N et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 1989; 80: 111-114
146 Nomura AM, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med 1980; 93: 537-540
147 Parsonnet J, Samloff IM, Nelson LM et al. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 1993; 2: 461-466
148 Parthasarathy G, Maroju NK, Kate V et al. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. Trop Gastroenterol 2007; 28: 166-170
149 Ren JS, Kamangar F, Qiao YL et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009; 58: 636-642
150 Sasazuki S, Inoue M, Iwasaki M et al. Japan Public Health Center Study Group Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case–control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1341-1347
151 Shiotani A, Iishi H, Uedo N et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005; 115: 463-469
152 So JB, Yeoh KG, Moochala S et al. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer 2002; 5: 228-232
153 Sugiu K, Kamada T, Ito M et al. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma. Dig Liver Dis 2006; 38: 303-307
154 Yoshihara M, Hiyama T, Yoshida S et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case–control study. Scand J Gastroenterol 2007; 42: 760-764
155 Hattori Y, Tashiro H, Kawamoto T et al. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995; 86: 1210-1215
156 Kitahara F, Kobayashi K, Sato T et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697
157 Westerveld BD, Pals G, Lamers CB et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987; 59: 952-958
158 You WC, Blot WJ, Zhang L et al. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 113-117
159 Yoshihara M, Sumii K, Haruma K et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998; 93: 1090-1096
160 Miki K, Ichinose M, Ishikawa KB et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84: 1086-1090
161 Miki K, Morita M, Sasajima M et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98: 735-739
162 Pharoah PD, Guilford P, Caldas C International Gastric Cancer Linkage Consortium Incidence of gastric cancer and breast cancer in CDH1 (Ecadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121: 1348-1353
163 Fitzgerald RC, Hardwick R, Huntsman D et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444
164 Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-449
165 Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138: 487-492
166 Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453
167 van Lier MG, Westerman AM, Wagner A et al. High cancer risk and increased mortality in patients with Peutz–Jeghers syndrome. Gut 2011; 60: 141-147
168 Offerhaus GJ, Giardiello FM, Krush AJ et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102: 1980-1982
169 Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2009; 102: 237-242
170 Bakir T, Can G, Erkul S et al. Stomach cancer history in the siblings of patients with gastric carcinoma. Eur J Cancer Prev 2000; 9: 401-408
171 La Vecchia C, Negri E, Franceschi S et al. Family history and the risk of stomach and colorectal cancer. Cancer 1992; 70: 50-55
172 Palli D, Galli M, Caporaso NE et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994; 3: 15-18
173 García-González MA, Lanas A, Quintero E et al. Gastric cancer susceptibility is not linked to pro- and anti-inflammatory cytokine gene polymorphisms in whites: a nationwide multicenter study in Spain. Am J Gastroenterol 2007; 102: 1878-1892
174 Dhillon PK, Farrow DC, Vaughan TL et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 2001; 93: 148-152
175 Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case–control study. Cancer Sci 2003; 94: 540-547
176 Eto K, Ohyama S, Yamaguchi T et al. Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. Eur J Sur Oncol 2006; 32: 743-748
177 Hong SH, Kim JW, Kim HG et al. Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer. J Prev Med Public Health 2006; 39: 135-140
178 Foschi R, Lucenteforte E, Bosetti C et al. Family history of cancer and stomach cancer risk. Int J Cancer 2008; 123: 1429-1432
179 Bernini M, Barbi S, Roviello F et al. Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. Gastric Cancer 2006; 9: 9-13
180 Rokkas T, Sechopoulos P, Pistiolas D et al. Helicobacter pylori infection and gastric histology in firstdegree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010; 22: 1128-1133
181 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
182 Figueiredo C, Machado JC, Pharoah P et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94: 1680-1687
183 Amieva MR, El-Omar EM. Host–bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323
184 Machado JC, Figueiredo C, Canedo P et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-371
185 Huang JQ, Zheng GF, Sumanac K et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-1644
186 Basso D, Zambon CF, Letley DP et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135: 91-99
187 El-Omar EM, Carrington M, Chow WH. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402
188 Yin M, Hu Z, Tan D et al. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res 2009; 1: 44-54
189 Persson C, Canedo P, Machado JC et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A a HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173: 259-270
190 Wang P, Xia HH, Zhang JY et al. Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer 2007; 120: 552-562
191 Camargo MC, Mera R, Correa P et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1674-1687
192 Xue H, Lin B, Ni P et al. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1604-1617
193 Kamangar F, Cheng C, Abnet CC et al. Interleukin-1B polymorphisms and gastric cancer risk – a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1920-1928
194 Loh M, Koh KX, Yeo BH et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 2009; 45: 2562-2568
195 Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255
196 Rugge M, Leandro G, Farinati F et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995; 76: 376-382
197 Rugge M, Cassaro M, Di Mario F et al. Interdisciplinary Group on Gastric Epithelial Dysplasia (IGGED) The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52: 1111-1116
198 de Jonge PJ, van Blankenstein M, Looman CW et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036
199 Stryker SJ, Wolff BG, Culp CE et al. Natural history of untreated colonic polyps. Gastroenterology 1987; 93: 1009-1013
200 Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (02) 1-5
201 Weinstein WM, Goldstein N. Gastric dysplasia and its management. Gastroenterology 1994; 107: 1543-1559
202 Ching CK. Can we justify resecting all gastric epithelial dysplastic lesions?. Gastroenterology 1995; 108: 1955-1956
203 Abraham SC, Montgomery EA, Singh VK et al. Gastric adenomas: intestinal type and gastric type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol 2000; 26: 1276-1285
204 Hosokawa O, Watanabe K, Hatorri M et al. Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy 2001; 33: 301-305
205 de Dombal FT, Price AB, Thompson H et al. The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut 1990; 31: 115-120
206 Sipponen P, Kekki M, Siurali M. Atrophic chronic gastritis and intestinal metaplasia in gastric cancer: comparison with a representative population sample. Cancer 1983; 52: 1062-1068
207 Hull MJ, Mino-Kenudson M, Nishioka NS et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol 2006; 30: 114-118
208 Kim YJ, Park JC, Kim JH et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy 2010; 42: 620-626
209 Kim ES, Jeon SW, Park SY et al. Where has the tumor gone? The characteristics of cases of negative pathologic diagnosis after endoscopic mucosal resection. Endoscopy 2009; 41: 739-745
210 Cassaro M, Rugge M, Gutierrez O et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95: 1431-1438
211 Morson BC. Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa. Br J Cancer 1955; 9: 377-385
212 Vannella L, Lahner E, Osborn J et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010; 31: 1042-1050
213 Lahner E, Bordi C, Cattaruzza MS et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 22: 471-481
214 Van Zanten SJ, Dixon MF, Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology 1999; 116: 1217-1229
215 Kimura A, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87-97
216 Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32: 1110-1113
217 Tosi P, Filipe MI, Luzi P et al. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol 1993; 169: 73-78
218 Ramesar KC, Sanders DS, Hopwood D. Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma. J Clin Pathol 1987; 40: 1287-1290
219 Conchillo JM, Houben G, de Bruïne A et al. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma?. Eur J Cancer Prev 2001; 10: 307-312
220 Nozaki K, Shimizu N, Ikehara Y et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003; 94: 235-239
221 Shimizu N, Ikehara Y, Inada K et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000; 60: 1512-1514
222 Maruta F, Sugiyama A, Ishizone S et al. Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils. J Gastroenterol 2005; 40: 104-105
223 Pimanov SI, Makarenko EV, Voropaeva AV et al. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol 2008; 23: 1666-1671
224 Rokkas T, Pistiolas D, Sechopoulos P et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12 (02) 32-38
225 de Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 26 (02) 25-35
226 Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253-260
227 Annibale B, Aprile MR, D’ambra G et al. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000; 14: 625-634
228 Satoh K, Kimura K, Takimoto T et al. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998; 3: 236-240
229 Correa P, Fontham ET, Bravo JC et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-1888
230 Mera R, Fontham ET, Bravo LE et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540
231 Wong BC, Lam SK, Wong WM. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194
232 Fuccio L, Zagari RM, Minardi ME et al. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133-141
233 Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009; 151: 121-128
234 Kim N, Park RY, Cho SI et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008; 42: 448-454
235 Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-1249
236 You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983
237 Take S, Mizuno M, Ishiki K et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037-1042
238 Take S, Mizuno M, Ishiki K et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46: 318-324
239 Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397
240 Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642
241 Toyokawa T, Suwaki K, Miyake Y et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol 2010; 25: 544-547
242 Yang HB, Sheu BS, Wang ST et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009; 104: 1642-1649
243 Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
244 Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
245 Malfertheiner P, Mégraud F, O’Morain C et al. European Helicobacter Pylori Study Group (EHPSG) Current concepts in the management of Helicobacter pylori infection – the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
246 Fock KM, Katelaris P, Sugano K. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600
247 Shin DW, Yun YH, Choi IJ et al. Cost–effectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer. Helicobacter 2009; 14: 536-544
248 Wang WH, Huang JQ, Zheng GF et al. Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784-1791
249 Tian W, Zhao Y, Liu S et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 2010; 19: 288-298
250 Leung WK, Ng EK, Chan FK et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006; 12: 4766-4772
251 Zhang LJ, Wang SY, Huo XH et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15: 2731-2738
252 Hung KH, Yang HB, Cheng HC et al. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 2010; 25: 48-53
253 Yanaoka K, Oka M, Yoshimura N et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 2010; 126: 1467-1473
254 Yang HB, Cheng HC, Sheu BS et al. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 25: 455-461
255 Wu CY, Wu MS, Kuo KN et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28: 2952-2957
256 Plummer M, Vivas J, Lopez G et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 2007; 99: 137-146
257 Mason J, Axon AT, Forman D et al. The cost–effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002; 16: 559-568
258 Parsonnet J, Harris RA, Hack HM et al. Modelling cost–effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 150-154
259 Davies R, Crabbe D, Roderick P et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci 2002; 5: 249-258
260 Roderick P, Davies R, Raftery J et al. The costeffectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003; 7: 1-86
261 Roderick P, Davies R, Raftery J et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003; 10: 148-156
262 Leivo T, Salomaa A, Kosunen TU et al. Cost–benefit analysis of Helicobacter pylori screening. Health Policy 2004; 70: 85-96
263 Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4: 709-716
264 Yeh JM, Kuntz KM, Ezzati M et al. Exploring the cost–effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009; 124: 157-166
265 Lee YC, Lin JT, Wu HM et al. Cost–effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 875-885
266 Lee HY, Park EC, Jun JK et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol 2010; 16: 245-250
267 Xie F, Luo N, Blackhouse G et al. Cost–effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care 2008; 24: 87-95
268 Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and 13C-urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. World J Gastroenterol 2008; 14: 3021-3027
269 Fendrick AM, Chernew ME, Hirth RA et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999; 159: 142-148
270 Yeh JM, Hur C, Kuntz KM et al. Cost–effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116: 2941-2953
271 Hassan C, Zullo A, Di Giulio E et al. Cost–effectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter 2010; 15: 221-226